# Merck

Type: Company (MRK)

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/merck
Canonical HTML page: https://getfinancebrief.com/entity/merck

## Timeline

- **2026-03-24**: Sentiment Review — Major analysts maintain existing price targets and ratings despite the earnings beat.
- **2026-03-16**: Analyst Upgrade — Wall Street Zen upgrades CDXS rating following financial results.
- **2026-03-11**: Q4 2025 Earnings — Codexis reports surprise profit and revenue beat.
- **2026-03-08**: TD Cowen Conference — CEO touts ECO Synthesis push and 2026 inflection targets.

## Recent coverage (3 stories)

### Healthcare +2.9% to Record, S&P +0.21% as Yields Ease
2026-08-20 00:48:31 · Sentiment: Very Bullish · Impact: 8/10 · Sources: 4

For finance readers, Aug. 19 was a case study in cross-asset relief: Treasury buyback news pulled the 30-year yield off its highest since 2007, feeding a 0.21% S&P 500 gain, while a more than 137% Moderna surge drove healthcare to a record 2.9% gain. The support for risk appetite masks a hawkish Fed minutes message and an unresolved long-term rate threat to AI-heavy valuations.
Full story: https://getfinancebrief.com/story/finance-markets-healthcare-record-yields-ease

### Merck Acquires Terns for $6.7B to Hedge Against Keytruda Patent Cliff
2026-03-25 16:35:43 · Sentiment: Bullish · Impact: 8/10 · Sources: 2

Merck has agreed to acquire Terns Pharmaceuticals for $6.7 billion in cash to bolster its oncology pipeline ahead of the 2028 patent expiration for its blockbuster drug, Keytruda. The deal centers on TERN-701, a promising leukemia treatment that positions Merck to compete directly with established players like Novartis.
Full story: https://getfinancebrief.com/story/merck-terns-acquisition-oncology-pipeline

### Codexis Holds Steady as ECO Synthesis Gains Traction Post-Q4 Earnings Beat
2026-03-24 23:00:38 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Codexis reported a significant Q4 2025 earnings beat, driven by its ECO Synthesis platform and expanding CDMO partnerships. Despite a raised 2026 revenue outlook and a surprise GAAP profit, analyst sentiment remains largely unchanged as the market awaits further commercial validation of its RNA manufacturing technology.
Full story: https://getfinancebrief.com/story/codexis-cdxs-earnings-analyst-sentiment-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.